Oxford Immunotec, with its U.S. headquarters in Marlborough, posted 27 percent revenue growth for 2015, but still fell short of analysts’ expectations with a loss of 29 cents per share in the fourth quarter.
The company’s fourth quarter revenue of $16.8 million represented 39 percent year-over-year growth and pushed the company to $62.8 million in revenue for the year. However, the commercial-stage diagnostics company still reported a net loss for the year of $24.5 million. This was up from $22.2 million for 2014 and represented a loss per share of $1.12.
Operating expenses for 2015 rose by $10 million over the previous year to $57.4 million, primarily due to the company expanding its sales force in the U.S. and Japan. Legal fees and costs from clinical studies also increased during the year.
